GLP-1 Receptor Agonist Market, By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Albiglutide, Semaglutide), By Route of Administration (Parenteral and Oral), By Application (Type 2 Diabetes Mellitus, Obesity, Liver Cirrhosis, Non-alcoholic Steatohepatitis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jul 2024

Code : CMI4632

Pages :170

Formats :

Excel and PDF

Industry : Pharmaceutical

Regional Analysis

GLP-1 Receptor Agonist Market Regional Insights

To learn more about this report, request sample copy

North America dominates the global GLP-1 receptor agonist market over with an estimated market share of 40.2% in 2024. The region has a highly developed healthcare infrastructure and availability of advanced treatment options. Healthcare expenditure is also higher in the U.S. and Canada compared to other parts of the world, enabling more patients to access costly drugs such as GLP-1 receptor agonists.

The presence of several leading pharmaceutical manufacturers and robust distribution networks in North America have boosted adoption of GLP-1 receptor agonists. Regional pharmaceutical players have undertaken initiatives to spread awareness among patients and physicians regarding the benefits of these drugs. This has significantly boosted the prescribing rates over the years.

Among regions, Asia Pacific is poised to register the fastest growth in the global GLP-1 receptor agonist market during the forecast period. Rapid economic development, rising healthcare expenditure, growing diabetes epidemic and increasing focus of international players on emerging Asian markets can drive the market growth.

Countries like China, India and South Korea offer huge export opportunities due to their large population base and increasing preference for quality American and European pharmaceutical products. International manufacturers have set up production facilities and are actively promoting GLP-1 drugs across Asia through collaborations with regional distribution partners. Many regional governments are also undertaking various initiatives to curb the diabetes burden and make advanced line of treatment easily available.